Human Genome Epidemiology Literature Finder
|
Records 1 - 18 (of 18 Records) |
| Query Trace: Dementia and CYP2D6[original query] |
|---|
| No evidence of an association between CYP2D6 polymorphisms among Japanese and dementia with Lewy bodies. Psychiatry and clinical neurosciences 2001 Apr 55 (2): 89-92. Furuno T, Kawanishi C, Iseki E, Onishi H, Sugiyama N, Suzuki K, Kosaka |
| Debrisoquine hydroxylase gene polymorphism (CYP2D6*4) in dementia with Lewy bodies. Journal of neurology, neurosurgery, and psychiatry 2003 Jan 74 (1): 135-6. Huckvale C, Richardson A M T, Mann D M A, Pickering-Brown S |
| Effects of smoking and cytochrome P450 2D6*10 allele on the plasma haloperidol concentration/dose ratio. Progress in neuro-psychopharmacology & biological psychiatry 2003 Sep 27 (6): 945-9. Ohara Koichi, Tanabu Shigeru, Yoshida Kimiko, Ishibashi Kazuhisa, Ikemoto Keiko, Shibuya Har |
| No association between CYP2D6 polymorphism and Alzheimer's disease in an Italian population. Pharmacological research 2006 Feb 53 (2): 162-5. Scordo Maria Gabriella, Dahl Marja-Liisa, Spina Edoardo, Cordici Francesco, Arena Maria Graz |
| CYP2D6 gene polymorphism as a probable risk factor for Alzheimer's disease and Parkinson's disease with dementia. Neurologia i neurochirurgia polska 0 41 (2): 113-21. Go?ab-Janowska Monika, Honczarenko Krystyna, Gawro?ska-Szklarz Barbara, Potemkowski Andrz |
| Association between inherited CYP2D6/2C19 phenotypes and anticholinergic measures in elderly patients using anticholinergic drugs. Therapeutic drug monitoring 2014 Feb 36 (1): 125-30. Kersten Hege, Wyller Torgeir B, Molden Esp |
| Predictive factors of clinical response to cholinesterase inhibitors in mild and moderate Alzheimer's disease and mixed dementia: a one-year naturalistic study. Journal of Alzheimer's disease : JAD 2015 45 (2): 609-20. Miranda Luís F J R, Gomes Karina B, Silveira Josianne N, Pianetti Gerson A, Byrro Ricardo M D, Peles Patrícia R H, Pereira Fernando H, Santos Thiago R, Assini Arthur G, Ribeiro Valéria V, Tito Pedro A L, Matoso Rafael O, Lima Thiago O L, Moraes Edgar N, Caramelli Pau |
| Clinical Response to Donepezil in Mild and Moderate Dementia: Relationship to Drug Plasma Concentration and CYP2D6 and APOE Genetic Polymorphisms. Journal of Alzheimer's disease : JAD 2017 55 (2): 539-549. Miranda Luís F J R, Gomes Karina B, Tito Pedro A L, Silveira Josianne N, Pianetti Gerson A, Byrro Ricardo M D, Peles Patrícia R H, Pereira Fernando H, Santos Thiago R, Assini Arthur G, Ribeiro Valéria V, Moraes Edgar N, Caramelli Pau |
| [Is it personalized treatment of dementia based on the CYP2D6 gene polymorphism possible?]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 0 118 (6. Vyp. 2): 90-94. Chebotareva A D, Levin O S, Markov D D, Sychev D A, Grishina E |
| Effect of CYP2D6 and CYP3A4 Genotypes on the Efficacy of Cholinesterase Inhibitors in Southern Chinese Patients With Alzheimer's Disease. American journal of Alzheimer's disease and other dementias 2019 5 34 (5): 302-307. Ma Suk Ling, Tang Nelson Leung Sang, Wat Karen Hong Yun, Tang Jenny Hoi Yin, Lau Ka Hin, Law Chun Bon, Chiu John, Tam Cindy Chi Woon, Poon Tin Keung, Lin Ka Leung, Kng Carolyn Poey Lyn, Kong Hing Leung, Chan Tak Yeung, Chan Wai Chi, Lam Linda Chiu |
| Influence of CYP2D6, CYP3A5, ABCB1, APOE polymorphisms and nongenetic factors on donepezil treatment in patients with Alzheimer's disease and vascular dementia. Pharmacogenomics and personalized medicine 2019 12 209-224. Yaowaluk Thitipon, Senanarong Vorapun, Limwongse Chanin, Boonprasert Rasda, Kijsanayotin Pornpim |
| Serum Concentrations of Cholinesterase Inhibitors in Patients With Alzheimer's Dementia Are Frequently Below the Recommended Levels. Frontiers in pharmacology 2020 11 691. Ortner Marion, Stange Marion, Schneider Heike, Schroeder Charlotte, Buerger Katharina, Müller Claudia, Dorn Bianca, Goldhardt Oliver, Diehl-Schmid Janine, Förstl Hans, Steimer Werner, Grimmer Ti |
| Are cytochrome P4502D6 and apolipoprotein E genotypes associated with long-term cognitive and functional changes in patients treated with donepezil? Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society 2020 Apr . Pamio Maria V, Trevisan Caterina, Pigozzo Sabrina, De Rui Marina, Devita Maria, Girardi Agostino, Manzato Enzo, Sergi Giuseppe, Coin Alessand |
| CYP2D6 Predicts Plasma Donepezil Concentrations in a Cohort of Thai Patients with Mild to Moderate Dementia. Pharmacogenomics and personalized medicine 2020 13 543-551. Chamnanphon Monpat, Wainipitapong Sorawit, Wiwattarangkul Teeravut, Chuchuen Phenphichcha, Nissaipan Kunathip, Phaisal Weeraya, Tangwongchai Sookjaroen, Sukasem Chonlaphat, Wittayalertpanya Supeecha, Gaedigk Andrea, Aniwattanapong Daruj, Chariyavilaskul Pajar |
| [Practical aspects of using donepezil in the treatment of dementia]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 2020 10 120 (9): 137-143. Chebotareva A D, Levin O |
| Impact of the CYP2D6 single nucleotide polymorphism on the concentration of and therapeutic response to donepezil in mild-to-moderate Alzheimer's disease. Journal of the Formosan Medical Association = Taiwan yi zhi 2021 Jun . Chou Ping-Song, Huang Ling-Chun, Hour Tzyh-Chyuan, Yen Chen-Wen, Yang Yuan-H |
| Association study identifies genetic determinants and non-genetic factors on steady-state plasma and therapeutic outcome of galantamine in mixed dementia. European journal of clinical pharmacology 2022 May . Yaowaluk Thitipon, Senanarong Vorapun, Limwongse Chanin, Boonprasert Rasda, Bunditvorapoom Duangkamon, Kaewsutthi Supannee, Kijsanayotin Pornpim |
| Impact of Plasma Donepezil Concentration on Behavioral and Psychological Symptoms of Dementia in Patients with Alzheimer's Disease. Dementia and geriatric cognitive disorders extra 0 11 (3): 264-272. Kagawa Yoshiyuki, Yamamoto Yoshiaki, Ueno Ayami, Inomata Kengo, Tezuka Mayu, Osawa Takashi, Yazawa Yasuharu, Maeda Toshio, Obi Tomoka |
- Page last reviewed:Oct 1, 2023
- Page last updated:Nov 28, 2023
- Content source: